XML 42 R33.htm IDEA: XBRL DOCUMENT
v3.23.2

Revenue (Disaggregation of Revenue by Product) (Details) - USD ($) | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | $ 8,312,100,000 | $ 6,488,000,000 | $ 15,272,100,000 | $ 14,298,000,000
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 5,531,400,000 | 3,934,800,000 | 9,967,600,000 | 9,109,400,000
Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 2,780,700,000 | 2,553,300,000 | 5,304,600,000 | 5,188,700,000
Diabetes |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 5,010,900,000 | 3,438,200,000 | 9,201,300,000 | 6,826,300,000
Diabetes | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 3,781,400,000 | 2,292,200,000 | 6,856,400,000 | 4,568,700,000
Diabetes | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 1,229,500,000 | 1,146,000,000 | 2,344,900,000 | 2,257,600,000
Trulicity® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 1,812,500,000 | 1,911,900,000 | 3,789,600,000 | 3,653,200,000
Trulicity® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 1,371,300,000 | 1,430,100,000 | 2,918,700,000 | 2,744,100,000
Trulicity® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 441,200,000 | 481,700,000 | 871,000,000.0 | 909,100,000
Mounjaro® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 979,700,000 | 16,000,000.0 | 1,548,200,000 | 16,000,000.0
Mounjaro® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 915,700,000 | 12,600,000 | 1,452,200,000 | 12,600,000
Mounjaro® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 64,000,000.0 | 3,400,000 | 96,000,000.0 | 3,400,000
Jardiance |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 668,300,000 | 461,000,000.0 | 1,245,800,000 | 880,400,000
Jardiance | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 386,100,000 | 250,700,000 | 715,600,000 | 480,400,000
Jardiance | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 282,200,000 | 210,300,000 | 530,200,000 | 400,000,000.0
Baqsimi |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 613,900,000 | 29,000,000.0 | 645,400,000 | 58,200,000
Baqsimi | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 606,200,000 | 21,800,000 | 629,300,000 | 44,300,000
Baqsimi | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 7,700,000 | 7,200,000 | 16,100,000 | 13,900,000
Humalog® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 440,400,000 | 447,100,000 | 901,400,000 | 1,065,300,000
Humalog® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 229,800,000 | 238,800,000 | 501,400,000 | 607,700,000
Humalog® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 210,600,000 | 208,300,000 | 400,000,000.0 | 457,600,000
Humulin® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 205,300,000 | 274,000,000.0 | 457,300,000 | 547,200,000
Humulin® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 144,300,000 | 202,300,000 | 343,100,000 | 392,800,000
Humulin® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 61,000,000.0 | 71,700,000 | 114,200,000 | 154,500,000
Basaglar® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 154,200,000 | 174,200,000 | 363,500,000 | 365,700,000
Basaglar® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 83,000,000.0 | 95,800,000 | 218,400,000 | 215,100,000
Basaglar® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 71,200,000 | 78,400,000 | 145,200,000 | 150,600,000
Other diabetes |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 136,600,000 | 125,000,000.0 | 250,100,000 | 240,300,000
Other diabetes | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 45,000,000.0 | 40,100,000 | 77,700,000 | 71,700,000
Other diabetes | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 91,600,000 | 85,000,000.0 | 172,200,000 | 168,500,000
Oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 1,671,000,000 | 1,368,700,000 | 3,027,000,000 | 2,721,700,000
Oncology | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 935,000,000.0 | 819,000,000.0 | 1,688,400,000 | 1,602,700,000
Oncology | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 736,000,000.0 | 549,800,000 | 1,338,600,000 | 1,119,000,000
Verzenio® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 926,800,000 | 588,500,000 | 1,677,700,000 | 1,057,900,000
Verzenio® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 588,600,000 | 384,300,000 | 1,049,600,000 | 685,700,000
Verzenio® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 338,200,000 | 204,200,000 | 628,000,000.0 | 372,100,000
Cyramza® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 260,300,000 | 231,300,000 | 497,000,000.0 | 461,500,000
Cyramza® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 115,000,000.0 | 92,600,000 | 215,600,000 | 171,800,000
Cyramza® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 145,300,000 | 138,600,000 | 281,400,000 | 289,700,000
Erbitux® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 162,500,000 | 140,800,000 | 292,400,000 | 263,400,000
Erbitux® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 145,500,000 | 125,100,000 | 264,200,000 | 234,700,000
Erbitux® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 17,000,000.0 | 15,700,000 | 28,100,000 | 28,700,000
Alimta® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 60,900,000 | 227,700,000 | 119,100,000 | 571,700,000
Alimta® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 17,900,000 | 171,700,000 | 38,000,000.0 | 425,900,000
Alimta® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 43,100,000 | 56,100,000 | 81,200,000 | 145,800,000
Other oncology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 260,500,000 | 180,400,000 | 440,800,000 | 367,200,000
Other oncology | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 68,000,000.0 | 45,300,000 | 121,000,000.0 | 84,600,000
Other oncology | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 192,400,000 | 135,200,000 | 319,900,000 | 282,700,000
Immunology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 928,500,000 | 796,500,000 | 1,706,300,000 | 1,544,600,000
Immunology | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 523,100,000 | 422,000,000.0 | 877,600,000 | 800,500,000
Immunology | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 405,400,000 | 374,500,000 | 828,600,000 | 744,100,000
Taltz® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 703,900,000 | 606,200,000 | 1,230,800,000 | 1,094,300,000
Taltz® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 472,300,000 | 411,600,000 | 784,500,000 | 718,800,000
Taltz® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 231,600,000 | 194,700,000 | 446,300,000 | 375,500,000
Olumiant® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 218,900,000 | 186,200,000 | 447,800,000 | 441,800,000
Olumiant® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 50,800,000 | 10,400,000 | 93,100,000 | 81,700,000
Olumiant® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 168,100,000 | 175,800,000 | 354,600,000 | 360,100,000
Other immunology |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 5,700,000 | 4,000,000.0 | 27,700,000 | 8,500,000
Other immunology | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 0 | 0 | 0 | 0
Other immunology | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 5,700,000 | 4,000,000.0 | 27,700,000 | 8,500,000
Neuroscience |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 387,200,000 | 389,900,000 | 747,700,000 | 787,700,000
Neuroscience | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 160,900,000 | 144,800,000 | 305,400,000 | 298,100,000
Neuroscience | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 226,300,000 | 245,200,000 | 442,300,000 | 489,500,000
Emgality® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 169,300,000 | 157,500,000 | 323,600,000 | 306,700,000
Emgality® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 118,800,000 | 108,600,000 | 227,500,000 | 216,900,000
Emgality® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 50,500,000 | 48,900,000 | 96,100,000 | 89,800,000
Other neuroscience |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 217,900,000 | 232,400,000 | 424,100,000 | 481,000,000.0
Other neuroscience | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 42,100,000 | 36,200,000 | 77,900,000 | 81,200,000
Other neuroscience | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 175,800,000 | 196,300,000 | 346,200,000 | 399,700,000
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 314,600,000 | 494,700,000 | 589,900,000 | 2,417,700,000
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 131,000,000.0 | 256,900,000 | 239,800,000 | 1,839,200,000
Other | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 183,500,000 | 237,900,000 | 350,100,000 | 578,500,000
Forteo® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 148,000,000.0 | 138,500,000 | 270,300,000 | 275,900,000
Forteo® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 97,400,000 | 78,500,000 | 168,000,000.0 | 148,700,000
Forteo® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 50,600,000 | 60,000,000.0 | 102,300,000 | 127,200,000
Cialis® |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 115,600,000 | 147,000,000.0 | 215,900,000 | 364,700,000
Cialis® | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 9,200,000 | 10,800,000 | 16,800,000 | 17,700,000
Cialis® | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 106,400,000 | 136,200,000 | 199,100,000 | 347,000,000.0
COVID-19 antibodies |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 0 | 129,100,000 | 0 | 1,598,900,000
COVID-19 antibodies | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 0 | 129,100,000 | 0 | 1,584,300,000
COVID-19 antibodies | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 0 | 0 | 0 | 14,700,000
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 51,000,000.0 | 80,100,000 | 103,700,000 | 178,200,000
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | 24,400,000 | 38,500,000 | 55,000,000.0 | 88,500,000
Other | Outside U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue | $ 26,500,000 | $ 41,700,000 | $ 48,700,000 | $ 89,600,000

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_DiabetesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_TrulicityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_MounjaroMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_JardianceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_BaqsimiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_HumalogMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_HumulinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_BasaglarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OtherDiabetesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_VerzenioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_CyramzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_ErbituxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_AlimtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_TaltzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OlumiantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_EmgalityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OtherNeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OtherProductTotalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_ForteoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_CialisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_COVID19AntibodiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_OtherProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |